Morgan Lewis

Related News

08/12/11 Q&A With Morgan Lewis' Steve Mahinka
Stephen Paul Mahinka is interviewed.
07/15/11 Morgan Lewis Serves as Co-Counsel to BHP Billiton on $12.1 Billion Acquisition of Petrohawk
Morgan Lewis served as co-counsel to BHP Billiton on a definitive agreement for BHP Billiton to acquire Petrohawk for $38.75 per share, representing a total equity value of approximately $12.1 billion and a total enterprise value of approximately $15.1 billion.
07/13/11 Morgan Lewis Team Advises Kinetic Concepts on Company’s $6.3 Billion Acquisition by Apax
Morgan Lewis advised Kinetic Concepts, Inc. (KCI), on a definitive merger agreement under which a consortium comprised of private equity funds will acquire KCI in a $6.3 billion transaction.
View all news
Photo of  Stephen Paul Mahinka

honors + affiliations

Trustee, Gettysburg College

Former Trustee, Johns Hopkins University

Former Member, Editorial Advisory Board, Food and Drug Law Journal

Former Executive Editor, Harvard International Law Journal

Listed as a leading lawyer in the Competition/Antitrust area in the PLC Cross-border Life Sciences Handbook (2010–11)

Listed as a leading lawyer in the Regulatory area in the PLC Cross-border Life Sciences Handbook (2010–11)

Listed as a leading lawyer in the PLC Cross-border Competition Law Handbook (2010–11)

Listed as a leading lawyer, Life Sciences: Competition/Antitrust; Recommended, Life Sciences: Regulatory; Recommended, Competition/Antitrust, PLC Which Lawyer? Yearbook 2011

Listed, International Who's Who of Life Sciences Lawyers 2011

Former Chair, American Bar Association, Antitrust Law Section, Committee on Labor Exemptions

Member, International Association of Privacy Professionals

Peer rated "AV" by Martindale Hubbell

Listed, Competition and Antitrust, EuroMoney Expert Guide to Leading Practitioners: China (2011)

bar admissions

  • District of Columbia
print profile

Stephen Paul Mahinka
Partner


Email: smahinka@morganlewis.com
Washington, D.C.
1111 Pennsylvania Ave., NW
Washington, DC 20004-2541
Phone: 202.739.5205
Fax: 202.739.3001

Stephen Paul Mahinka is the chair of Morgan Lewis's Life Sciences and Healthcare Interdisciplinary Group. He also is a member of both the Antitrust Practice and the FDA and Healthcare Practice. The firm's Life Sciences and Healthcare Group, one of the nation's largest, is consistently ranked among the world's leading practices. Mr. Mahinka has practiced in both the antitrust and FDA/healthcare areas throughout his career, and is the founder of the firm's FDA and Healthcare Practice and a former leader of the firm's Antitrust Practice. He is also co-coordinator of the firm's Advertising, Consumer Protection, and Privacy Practice.

In the antitrust area, Mr. Mahinka's practice includes counseling and litigation concerning mergers, joint ventures, and other collaboration agreements; pricing and price discrimination; marketing and advertising; monopolization; Department of Justice, Federal Trade Commission, and state investigations; FTC and state consumer protection issues; trade associations; the labor-antitrust exemption; and the application of the antitrust laws to regulated industries, particularly life sciences/healthcare and energy. He has testified before government agencies regarding competition issues in both the United States and Canada.

In the FDA/healthcare area, Mr. Mahinka's practice focuses on regulatory, transactional, and compliance matters throughout the product lifecycle, including approval, acquisition, licensing, marketing, distribution, pricing, and enforcement concerning prescription and OTC drugs, biologics, biosimilars, food and food additives, GRAS substances and packaging, medical devices, and dietary supplements; FTC, DOJ, and state investigations; Hatch-Waxman matters; FTC, FDA, and state consumer protection matters; joint venture matters regarding healthcare providers; and healthcare reform law issues. He has assisted with numerous life sciences transactions, including acquisitions, collaborations, and licensing.

As part of his competition practice, he has made numerous filings to the Committee on Foreign Investment in the United States (CFIUS) concerning transfers of national security and critical infrastructure assets to foreign purchasers. Over the past few years, Mr. Mahinka has obtained clearances for nearly 40 transactions, representing foreign buyers and domestic sellers, in acquisitions, investments, and joint ventures. He has substantial experience with CFIUS and related U.S. government agencies in mitigating Foreign Ownership, Control, and Influence (FOCI) issues that may be presented as conditions to clearance of a proposed transaction.

Mr. Mahinka has published nearly 60 articles on antitrust and FDA/healthcare matters. He is a co-author of Food and Drug Law and Regulation (Food and Drug Law Institute, Second Edition 2011), of Life Sciences Mergers and Acquisitions (Aspatore, 2008), and of Winning Antitrust Strategies (Aspatore, 2004), and a contributing author of the ABA Antitrust Section's Pharmaceutical Industry Antitrust Handbook (2009). 

Mr. Mahinka has presented more than 80 speeches on antitrust, FDA/healthcare, and CFIUS matters in the United States and Japan, at programs sponsored by such groups as the Food and Drug Law Institute, the American Bar Association's Section of Antitrust Law, the Biotechnology Industry Organization, the Japan-America Society, the Washington Legal Foundation, the Regulatory Affairs Professionals Society, IHOKEN (the Japanese pharmaceutical industry lawyers' association), and the Edison Electric Institute.

He is a former member of the firm’s Advisory Board and the firm’s Finance Committee and a former vice-chair of the Washington, D.C. office Management Committee.

Mr. Mahinka served as a law clerk to the Chief Justice of the Massachusetts Appeals Court.

Mr. Mahinka is admitted to practice in the District of Columbia.

education

  • Harvard Law School, 1974, J.D.
  • Johns Hopkins University, 1971, B.A., Phi Beta Kappa